12 / 26
Page 50
June 28-29, 2019 | Oslo, Norway
Volume 08
Journal of Medical and Health Sciences | ISSN : 2319-
Breast Pathology and Cancer, Gynecology and Obstetrics Pathology, Palliativecare and Gerontology 2019
Joint Event
Breast Pathology & Cancer
Palliativecare & Gerontology
Gynecology and Obstetrics Pathology
RRJMHS 2019, Volume 08
Evaluation of the effects of taking evening primrose oil (EPO) capsules from 38
th
week of
pregnancy in nulliparous women (labor/induction/outcomes)
Amirkavian Moaveni
University of Kurdistan, Iran
Introduction:
Evening primrose (Oenthera biennis) is a medical plant fromNorthAmerica. Evening primrose
oil (EPO) contains gamma-linolenic acid (GLA) that stimulates the production of prostaglandins in body. It
is believed initiate cervical ripening due to EPO. The aim of this study was to evaluate the effects of taking
EPO from 38
th
week of pregnancy in nulliparous women on the type of delivery, induction need, duration of
induction, labor duration, neonatal outcomes, quality of labor and maternal complications.
Methods:
In double-blind randomized controlled trial performed in Sanandaj Besat Hospital, 440 nulliparous
pregnant women in 38
th
week of pregnancy and with bishop score of <6 were divided randomly in to two
groups (220 in each). First group took EPO 1g Q12h and next group took placebo. In the other part of the
study women that did not enter to labor phase until 40
th
week of pregnancy from both groups, were evaluated
during the induction by oxytocin to check the effects of EPO on induction and outcomes.
Results:
Normal labor (vaginal or cesarean delivery) without needed of induction was occurred in 134 (60.9%)
women of EPO group (15 C/S (11.19%) and 119 NVD (88.80%)) and 122 (55.45%) women of placebo group
(21 C/S (17.21%) and 101 NVD (82.78%)). Frequency of cesarean section deliveries decreased significantly
in EPO group compared with placebo group. 86 (39.09%) women from EPO group and 98 (44.54%) women
from placebo group needed induction (oxytocin) for delivery that the rate of successful vaginal delivery was
significantly higher in EPO group and duration of active phase, second stage and third stage of labor were
shorter in EPO group. No significant difference of neonatal factors and outcomes (such as 1
st
and 5
th
min
Apgar score/need for NICU admission) were found between the EPO and placebo groups.
Conclusions:
This research showed significant positive results of taking EPO capsules from 38
th
week of
pregnancy in nulliparous women, on the type of delivery (decrease cesarean section), length of labor, need
for induction, duration of induction and success rate.